NCT00697853View on ClinicalTrials.gov

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

PHASE2CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

November 30, 1998

Primary Completion Date

July 31, 1999

Conditions

Hepatitis B

Interventions

BIOLOGICAL

Engerix™-B

3-dose intramuscular injection

BIOLOGICAL

HBV-MPL vaccine 208129

2-dose intramuscular injection

Trial Locations (1)

Unknown

GSK Clinical Trial Call Center, Brussels

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00697853 - Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults | Biotech Hunter | Biotech Hunter